Richard  Ferrari net worth and biography

Richard Ferrari Biography and Net Worth

Director of HeartBeam

Richard Ferrari joined our Board in 2019 and was appointed Executive Director of the Board of Directors in June 2021. Mr. Ferrari combines over 40 years of experience in Medical Device Start-ups as CEO, and entrepreneur. Also Mr. Ferrari is co-founder of De Novo Ventures which has $650M under management and has been Managing Director since 2000. Mr. Ferrari has also co-founded 6 more companies, two of which have been successful IPO’s and subsequent acquisitions, CTS one of the companies he co-founded was the fastest start-up to an IPO in the last 22 years in the medical device industry. Mr. Ferrari most recently from 2018 to 2021 was Chairman and CEO of PQ Bypass which was recently acquired by Endologix. Mr. Ferrari sits on the board of Pulmonx, a public company and is the Chairman of the Compensation Committee. Additionally, he is Executive Chairman of Tenon Medical, Vice-Chairman of ABS Interventional, Executive Chairman of Medlumics, and holds board positions with several other medical device start-ups. Mr. Ferrari has an undergraduate degree from Ashland University and an MBA from University of South Florida.

What is Richard Ferrari's net worth?

The estimated net worth of Richard Ferrari is at least $107.29 thousand as of April 16th, 2026. Mr. Ferrari owns 291,636 shares of HeartBeam stock worth more than $107,293 as of September 30th. This net worth evaluation does not reflect any other assets that Mr. Ferrari may own. Learn More about Richard Ferrari's net worth.

How do I contact Richard Ferrari?

The corporate mailing address for Mr. Ferrari and other HeartBeam executives is 1000 CEDAR HOLLOW ROAD, MALVERN PA, 19355. HeartBeam can also be reached via phone at 610-729-7000 and via email at [email protected]. Learn More on Richard Ferrari's contact information.

Has Richard Ferrari been buying or selling shares of HeartBeam?

Richard Ferrari has not been actively trading shares of HeartBeam during the last quarter. Most recently, on Thursday, April 16th, Richard Ferrari bought 62,500 shares of HeartBeam stock. The stock was acquired at an average cost of $0.80 per share, with a total value of $50,000.00. Following the completion of the transaction, the director now directly owns 291,636 shares of the company's stock, valued at $233,308.80. Learn More on Richard Ferrari's trading history.

Who are HeartBeam's active insiders?

HeartBeam's insider roster includes Richard Ferrari (Director), Michael Jaff (Director), Marga Ortigas-Wedekind (Director), and Branislav Vajdic (President, Director). Learn More on HeartBeam's active insiders.

Are insiders buying or selling shares of HeartBeam?

In the last year, HeartBeam insiders bought shares 7 times. They purchased a total of 1,118,750 shares worth more than $895,000.00. In the last year, insiders at the medical research company sold shares 3 times. They sold a total of 307,146 shares worth more than $1,077,090.03. The most recent insider tranaction occured on April, 16th when CFO Tim Cruickshank bought 31,250 shares worth more than $25,000.00. Insiders at HeartBeam own 18.0% of the company. Learn More about insider trades at HeartBeam.

Information on this page was last updated on 4/16/2026.

Richard Ferrari Insider Trading History at HeartBeam

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/16/2026Buy62,500$0.80$50,000.00291,636View SEC Filing Icon  
2/14/2025Buy29,412$1.70$50,000.40179,136View SEC Filing Icon  
See Full Table

Richard Ferrari Buying and Selling Activity at HeartBeam

This chart shows Richard Ferrari's buying and selling at HeartBeam by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

HeartBeam Company Overview

HeartBeam logo
BioTelemetry, Inc., a remote medical technology company, provides remote cardiac monitoring, remote blood glucose monitoring, centralized core laboratory services for clinical trials, and original equipment manufacturing services for healthcare and clinical research customers worldwide. It operates in two segments, Healthcare and Research. The Healthcare segment focuses on the remote cardiac monitoring to identify cardiac arrhythmias or heart rhythm disorders. This segment offers mobile cardiac telemetry services; and event monitoring services, which enable physicians to prescribe wireless event, digital loop event, memory loop event, memory loop event, and non-loop event monitors. It also provides traditional and extended Holter, pacemaker, international normalized ratio, implantable loop recorder, and other implantable cardiac device monitoring services. It serves cardiologists, electrophysiologists, neurologists, and primary care physicians. The Research segment offers laboratory services, such as cardiac monitoring, imaging, scientific consulting, and data management services for drug and medical device trials. Its centralized services comprise electrocardiogram, Holter monitoring, ambulatory blood pressure monitoring, echocardiography, multigated acquisition scan, imaging, protocol development, expert reporting, and statistical analysis. It also provides support services, such as project coordination, setup and management, equipment rental, data transfer, processing, analysis, and 24/7 customer support and site training. The company also focuses on manufacturing, testing, and marketing of cardiac devices and blood glucose monitoring devices, as well as offers contract manufacturing services. BioTelemetry, Inc. was founded in 1994 and is headquartered in Malvern, Pennsylvania.
Read More

Today's Range

Now: $0.37
Low: $0.36
High: $0.38

50 Day Range

MA: $0.47
Low: $0.36
High: $0.59

2 Week Range

Now: $0.37
Low: $0.36
High: $4.00

Volume

4,039 shs

Average Volume

973,169 shs

Market Capitalization

$20.68 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A